Exagen price to sales ratio XGN
Market value divided by revenue over the last twelve months, since 2020.
- Today, Nov 2, 2026
- 2.9×
- 6-year median
- 1.7×
- Against its 6-year history
- 69th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 0.4× to 6.4×
- Peer median
- 1.6×
Exagen's price to sales ratio is 2.9× as of Nov 2, 2026.
That is above its 6-year median of 1.7×, higher than on 69% of days in the last 6 years.
Over that time it ranged from 0.4× in Apr 2024 to 6.4× in Mar 2021.
The median for 10 healthcare stocks of a similar size is 1.6×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 2.9× | 1.0× | 3.0× |
| 2025 | 2.2× | 1.0× | 4.5× |
| 2024 | 1.5× | 0.4× | 1.8× |
| 2023 | 0.7× | 0.5× | 1.2× |
| 2022 | 0.9× | 0.8× | 3.5× |
| 2021 | 3.9× | 3.1× | 6.4× |
| 2020 | 4.2× | 3.4× | 5.3× |
Against its peers
Companies in Healthcare nearest Exagen's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| XGNExagen | 2.9× |
| PLXProtalix BioTherapeutics | 2.6× |
| NATRNatures Sunshine Products | 0.4× |
| ELMDElectromed | 3.0× |
| PDEXPro DEX | 2.3× |
| UTMDUtah Medical Products | 6.2× |
| INFUInfuSystem | 1.9× |
| CYHCommunity Health Systems | 0.0× |
| EMBCEmbecta | 0.3× |
| VMDViemed Healthcare | 1.2× |
| CRMDCorMedix | 0.9× |
| Peer median | 1.6× |
Where Exagen ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Exagen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.